Detailed explanation of whether Asciminib/Asciminib has been included in medical insurance and reimbursement policy

Asciminib (Asciminib, also known as Asciminib) is a new generation of targeted therapy drug, mainly used to treat patients with chronic myelogenous leukemia (CML) who are resistant or intolerant to previous treatments. Different from traditional tyrosine kinase inhibitors (TKIs), asinib is a "STI" targeted drug with a unique mechanism of action. It can target the allosteric site of ABL protein, thereby effectively inhibiting the proliferation of tumor cells. This innovative mechanism enables it to show good efficacy in the treatment of multiple drug-resistant mutations (such as the T315I mutation), so it has attracted the attention of clinicians and patients since its launch.

At present, Aceminib has been officially launched in China, but it has not yet been included in the national medical insurance directory, which means that patients need to bear all the drug costs out of their own pocket when using the drug. Since this drug is an innovative drug, its price is relatively high. The specific price may vary slightly depending on the hospital and region. It is recommended that patients go to the local hospital pharmacy to inquire about the actual cost of purchasing the drug. The lack of coverage by medical insurance also means that the financial burden is relatively large for patients who take medicine for a long time, which to a certain extent affects the enthusiasm of some patients to use it.

In the international market, the original drug Asinib mainly comes from Europe, and the price is very high, usually around tens of thousands of yuan per box, which is a large expense for most patients. In order to reduce costs, many patients will also pay attention to more affordable generic drugs. At present, a generic drug of Asnib has been launched in Laos. Its price is about more than 4,000 yuan, which is several times cheaper than the original drug. At the same time, the drug ingredients are basically the same as the original drug, so it has a certain appeal among patients with heavy financial burdens.

Overall, the accessibility of Asnib in China is gradually improving, but as it is not yet included in medical insurance, patients still have to face high out-of-pocket costs. In the future, as the clinical use of this drug increases and medical insurance negotiations advance, it is expected to be included in the medical insurance directory, further reducing the financial pressure on patients. Prior to this, when patients choose drug purchase channels, they should give priority to regular hospitals and legal overseas channels to ensure that the source of drugs is reliable and the treatment is safe and effective.

Reference link:https://www.drugs.com